Literature DB >> 6121566

Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

A C Tweddel, R G Murray, D Pearson, W Martin, I Hutton.   

Abstract

?The cardiovascular effects of the cardioselective beta, agonist prenalterol have been studied in nine patients with severe chronic congestive cardiac failure and in six patients with left ventricular dysfunction resulting from previous myocardial infarction. In the patients with cardiac failure intravenous prenalterol in a dosage of 1.5 microgram/kg bodyweight increased the cardiac index from 1.8 +/- 0.1 to 21.+/- 0.1 1/min per m2 and the left ventricular ejection fraction from 22 +/- 3 to 28 +/- 3%. There was a modest but significant increase in heart rate from 76 +/- 3 to 87 +/- 4 beats/min. Systemic vascular resistance fell from 2285 +/- 51 to 2041 +/- 534 dynes s-1 cm-5. On exercise, the left ventricular filling pressure fell from 33 +/- 6 to 26 +/- 3 and both cardiac index and stroke index increased by 13% and 16%, respectively. There was no significant change in heart rate or systemic blood pressure. In the patients with left ventricular dysfunction, coronary sinus blood flow increased from 107 +/- 11 to 133 +/- 12 ml/min but the increase in myocardial oxygen consumption was small and not significant (11.6 +/- 1.2 and 14.5 +/- 1.9 ml/min). In all patients there was no evidence that prenalterol was arrhythmogenic.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121566      PMCID: PMC481150          DOI: 10.1136/hrt.47.4.375

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  24 in total

Review 1.  Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.

Authors:  L I Goldberg; Y Y Hsieh; L Resnekov
Journal:  Prog Cardiovasc Dis       Date:  1977 Jan-Feb       Impact factor: 8.194

2.  A comparison of cardiovascular effects of dobutamine and isoprenaline after open heart surgery.

Authors:  F Kersting; F Follath; R Moulds; J Mucklow; R McCloy; J Sheares; C Dollery
Journal:  Br Heart J       Date:  1976-06

Review 3.  Vasodilator therapy of cardiac failure (second of two parts).

Authors:  J N Cohn; J A Franciosa
Journal:  N Engl J Med       Date:  1977-08-04       Impact factor: 91.245

Review 4.  Digitalis (fourth of four parts).

Authors:  T W Smith; E Haber
Journal:  N Engl J Med       Date:  1973-11-22       Impact factor: 91.245

5.  Effects of intravenously administered digoxin on mild left ventricular failure in acute myocardial infarction in man.

Authors:  M Hodges; G C Friesinger; R C Riggins; G R Dagenais
Journal:  Am J Cardiol       Date:  1972-06       Impact factor: 2.778

6.  Measurement of coronary sinus blood flow by continuous thermodilution in man.

Authors:  W Ganz; K Tamura; H S Marcus; R Donoso; S Yoshida; H J Swan
Journal:  Circulation       Date:  1971-08       Impact factor: 29.690

Review 7.  The failing myocardium. I. Drug management.

Authors:  H S Loeb; S H Rahimtoola; R M Gunnar
Journal:  Med Clin North Am       Date:  1973-01       Impact factor: 5.456

8.  Influence of dobutamine on regional myocardial blood flow and ventricular performance during acute and chronic myocardial ischemia in dogs.

Authors:  J T Willerson; I Hutton; J T Watson; M R Platt; G H Templeton
Journal:  Circulation       Date:  1976-05       Impact factor: 29.690

9.  Hemodynamic effect of dobutamine in patients with severe heart failure.

Authors:  N Akhtar; E Mikulic; J N Cohn; M H Chaudhry
Journal:  Am J Cardiol       Date:  1975-08       Impact factor: 2.778

10.  Effects of dobutamine in patients with acute myocardial infarction.

Authors:  T A Gillespie; H D Ambos; B E Sobel; R Roberts
Journal:  Am J Cardiol       Date:  1977-04       Impact factor: 2.778

View more
  5 in total

Review 1.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

2.  Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.

Authors:  E J Sainsbury; D Fitzpatrick; H Ikram; M G Nicholls; E A Espiner; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.

Authors:  P J Currie; M J Kelly; K Middlebrook; J Federman; E Sainsbury; J Ashley; A Pitt
Journal:  Br Heart J       Date:  1984-05

4.  Acute haemodynamic effects of oral prenalterol in severe heart failure.

Authors:  M C Petch; C Wisbey; O Ormerod; C Scott; R M Goodfellow
Journal:  Br Heart J       Date:  1984-07

5.  Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects.

Authors:  S Rasmussen; P F Høilund-Carlsen; B Hesse; O J Hartling; J Fabricius; H Dige-Petersen; J Giese
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.